APA (7th ed.) Citation

Valent, P., Hadzijusufovic, E., Schernthaner, G., Wolf, D., Rea, D., & le Coutre, P. (2015). Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 125(6), 901-906. https://doi.org/10.1182/blood-2014-09-594432

Chicago Style (17th ed.) Citation

Valent, Peter, Emir Hadzijusufovic, Gerit-Holger Schernthaner, Dominik Wolf, Delphine Rea, and Philipp le Coutre. "Vascular Safety Issues in CML Patients Treated with BCR/ABL1 Kinase Inhibitors." Blood 125, no. 6 (2015): 901-906. https://doi.org/10.1182/blood-2014-09-594432.

MLA (9th ed.) Citation

Valent, Peter, et al. "Vascular Safety Issues in CML Patients Treated with BCR/ABL1 Kinase Inhibitors." Blood, vol. 125, no. 6, 2015, pp. 901-906, https://doi.org/10.1182/blood-2014-09-594432.